Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Recent Posts
- Cambridge and BIOTEC Researchers Join Thailand-International Networks to Advance One Health Action against Streptococcus suis: From Research to Prevention
07/17/2026 - Pirbright-BIOTEC African Swine Fever Technical Workshop
06/29/2026 - BIOTEC Welcomes Australia’s Chief Scientist to Strengthen Thailand–Australia Collaboration in Biotechnology and Research Infrastructure
06/23/2026